Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs

British Journal of Cancer

Volumn 82, Issue 4, 2000, Pages 966-972

  Screnci, D ^a   McKeage, M J ^a   Galettis, P ^a   Hambley, T W ^b   Palmer, B D ^c   Baguley, B C ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Cancer chemotherapy; Inductively coupled plasma mass spectrometry; Neurotoxicity; Platinum; Structure activity relationships

Indexed keywords

CARBOPLATIN; CISPLATIN; NEUROTOXIN; OXALIPLATIN; PLASMA PROTEIN; PLATINUM DERIVATIVE; SATRAPLATIN; TETRAPLATIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; FEMALE; HUMAN; HYDROPHOBICITY; MASS SPECTROMETRY; NEUROTOXICITY; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; RAT; SCIATIC NERVE; SENSORY NERVE CONDUCTION; SPINAL CORD; SPINAL GANGLION; STRUCTURE ACTIVITY RELATION; SURAL NERVE;

EID: 0033962280     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.1026     Document Type: Article

References (20)

1. Albert A (1979) Selective Toxicity: The Physiochemical Basis Of Therapy. Chapman and Hall: London
2. Borch RF (1987) The platinum anti-tumour drugs. In: Metabolism and Action of Anti-Cancer Drugs, Powis G and Prough RA (eds), pp. 163-193. Taylor and Francis: London
3. Braumann T (1986) Determination of hydrophobic parameters by reverse-phase liquid chromatography: theory, experimental techniques and applications in studies on quantitative structure-activity relationships. J Chromatogr 373: 191-225
4. Canetta R, Rozencweig MO and Carter SK (1985) Carboplatin: the clinical spectrum to date. Cancer Treat Rev 12: (Suppl A) 125-136
5. Dearden JC and Bresnen GM (1988) The measurement of partition coefficients. Quant Struct-act Rel 7: 133-144
6. Einhorn IH (1997) Testicular cancer: an oncological success story. Clin Cancer Res 3: 2630-2632
7. Gerritsen van der Hoop R, van der Burg Mel, Ten Bokkel Huinink WW, van Houwelingen JC and Neijt JP (1990) Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 66: 1697-1702
8. Goyer RA (1996) Toxic effects of metals. In: Casarett and Doull's Toxicology: The Basic Science of Poisons, Klaassen CD (ed.) pp. 691-736. McGraw-Hill: New York
9. Gregg RW, Molepa JM, Monpetit VJA, Mikael NZ, Redmond D, Gadia M and Stewart DJ (1992) Cisplatin neurotoxicity: The relationship between dosage, time and platinum concentration in neurological tissues, and morphologic evidence of toxicity. J Clin Oncol 10: 795-803
10. Judson IR, Cerny T, Epelbaum R, Dunlop D, Smyth J, Schaefer B, Roelvink M, Kaplan S and Hanauske A (1997) Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation. Ann Oncol 8: 604-606
11. McGuire WP and Ozols RF (1998) Chemotherapy for advanced ovarian cancer. Semin Oncol 25: 340-348
12. McKeage MJ (1995) Comparative adverse effect profiles of platinum drugs. Drug Saf 13: 228-244
13. McKeage MJ, Boxall F, Jones M and Harrap KR (1994) Lack of neurotoxicity of oral bis-acetato-ammine-dichloro-cyclohexylamine-platinun(IV) (JM216) in comparison to cisplatin and tetraplatin in the rat. Cancer Res 54: 629-631
14. Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu J, Brienza S, Itzhaki M, Metzger G, N'Daw D and Vignoud J (1996) Two consecutive phase II studies of oxaliplatin (1-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7: 95-98
15. O'Rourke TJ, Weiss GR, New P, Burris HA, Rodriguez G, Eckhart J, Hardy J, Kuhn JG, Fields S and Clark GM (1998) Phase I clinical trial of ormaplatin (tetraplatin NSC 363812). Anticancer Drugs 5: 520-526
16. Schilder RJ, La Creta FP, Perez RP, Johnson SW, Brennan JM, Rogatko A, Nash S, McAleer C, Hamilton TC and Rody D (1994) Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and 8 schedule. Cancer Res 54: 709-717
17. Screnci D, Er HM, Hambley TH, Galettis P, Brouwer W and McKeage MJ (1997) Stereo-selective peripheral sensory neurotoxicity of diaminocyclohexane platinum enantiomers related to ormaplatin and oxaliplatin. Br J Cancer 76: 502-510
18. Screnci D, Galettis P, Baguley BC and McKeage MJ (1998) Optimization of an ICP-MS assay for the detection of trace levels of platinum in peripheral nerves. Atomic Spectrose 19: 172-175
19. Thompson SW, Davis LE, Kornfeld M, Hilger RD and Standefer JC (1984) Cisplatin neurotoxicity: clinical, electrophysiologic, morphologic and toxicologic studies. Cancer 54: 1269-1275
20. van der Vijgh WJF and Klein I (1986) Protein binding of five platinum compounds: comparison of two ultrafiltration systems. Cancer Chemother Pharmacol 18: 129-132